Outcomes in COVID-19 iC1e/K studies

0 0.5 1 1.5+ All studies 0% 1 20 Improvement, Studies, Patients Relative Risk Mortality 0% 1 20 RCTs 0% 1 20 Late 0% 1 20 IC1e/K for COVID-19 c19early.org November 2025 FavorsiC1e/K Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mansour (RCT) 0% 1.00 [0.07-13.9] death 1/10 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.07-13.9] 1/10 1/10 no change All studies 0% 1.00 [0.07-13.9] 1/10 1/10 no change 1 iC1e/K COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors iC1e/K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mansour (RCT) 0% 1.00 [0.07-13.9] 1/10 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.07-13.9] 1/10 1/10 no change All studies 0% 1.00 [0.07-13.9] 1/10 1/10 no change 1 iC1e/K COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors iC1e/K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mansour (RCT) 0% 1.00 [0.07-13.9] death 1/10 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.07-13.9] 1/10 1/10 no change All studies 0% 1.00 [0.07-13.9] 1/10 1/10 no change 1 iC1e/K COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors iC1e/K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mansour (RCT) -35% 1.35 [0.72-2.55] no disch. 10 (n) 10 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.36 Late treatment -35% 1.35 [0.72-2.55] 10 (n) 10 (n) 35% higher risk All studies -35% 1.35 [0.72-2.55] 10 (n) 10 (n) 35% higher risk 1 iC1e/K COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.36 Favors iC1e/K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mansour (RCT) 0% 1.00 [0.07-13.9] death 1/10 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.07-13.9] 1/10 1/10 no change All studies 0% 1.00 [0.07-13.9] 1/10 1/10 no change 1 iC1e/K COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors iC1e/K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mansour (RCT) 0% 1.00 [0.07-13.9] 1/10 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.07-13.9] 1/10 1/10 no change All studies 0% 1.00 [0.07-13.9] 1/10 1/10 no change 1 iC1e/K COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors iC1e/K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mansour (RCT) 0% 1.00 [0.07-13.9] death 1/10 1/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.07-13.9] 1/10 1/10 no change All studies 0% 1.00 [0.07-13.9] 1/10 1/10 no change 1 iC1e/K COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors iC1e/K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mansour (RCT) 0% 1.00 [0.07-13.9] death 1/10 1/10 Improvement, RR [CI] Treatment Control Mansour (RCT) -35% 1.35 [0.72-2.55] no disch. 10 (n) 10 (n) IC1e/K COVID-19 outcomes c19early.org November 2025 Favors iC1e/K Favors control